These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 26130305)

  • 41. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
    Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
    Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
    Nishikawa T; Watanabe R; Kitano Y; Yamamichi A; Motomura K; Ohka F; Aoki K; Hirano M; Kato A; Yamaguchi J; Maeda S; Kibe Y; Saito R; Wakabayashi T; Kato Y; Sato S; Ogino T; Natsume A; Ito I
    Brain Tumor Pathol; 2022 Jan; 39(1):14-24. PubMed ID: 34826036
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interlaboratory comparison of IDH mutation detection.
    van den Bent MJ; Hartmann C; Preusser M; Ströbel T; Dubbink HJ; Kros JM; von Deimling A; Boisselier B; Sanson M; Halling KC; Diefes KL; Aldape K; Giannini C
    J Neurooncol; 2013 Apr; 112(2):173-8. PubMed ID: 23358936
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up.
    Rajeswarie RT; Rao S; Nandeesh BN; Yasha TC; Santosh V
    J Clin Pathol; 2018 Apr; 71(4):323-329. PubMed ID: 28801347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Non-canonical IDH1 and IDH2 mutations: a clonal and relevant event in an Italian cohort of gliomas classified according to the 2016 World Health Organization (WHO) criteria.
    Visani M; Acquaviva G; Marucci G; Paccapelo A; Mura A; Franceschi E; Grifoni D; Pession A; Tallini G; Brandes AA; de Biase D
    J Neurooncol; 2017 Nov; 135(2):245-254. PubMed ID: 28748342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunohistochemical expression of IDH1 in gliomas: a tissue microarray-based approach.
    Sipayya V; Sharma I; Sharma KC; Singh A
    J Cancer Res Ther; 2012; 8(4):598-601. PubMed ID: 23361281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.
    Capper D; Weissert S; Balss J; Habel A; Meyer J; Jäger D; Ackermann U; Tessmer C; Korshunov A; Zentgraf H; Hartmann C; von Deimling A
    Brain Pathol; 2010 Jan; 20(1):245-54. PubMed ID: 19903171
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J; Meyer J; Mueller W; Korshunov A; Hartmann C; von Deimling A
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Detection of IDH1 and IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies.
    Horbinski C; Kelly L; Nikiforov YE; Durso MB; Nikiforova MN
    J Mol Diagn; 2010 Jul; 12(4):487-92. PubMed ID: 20431032
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Qualitative and Quantitative Analysis of IDH1 Mutation in Progressive Gliomas by Allele-Specific qPCR and Western Blot Analysis.
    Perrech M; Dreher L; Röhn G; Stavrinou P; Krischek B; Toliat M; Goldbrunner R; Timmer M
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819828396. PubMed ID: 30943868
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Detection of IDH1 mutation in the plasma of patients with glioma.
    Boisselier B; Gállego Pérez-Larraya J; Rossetto M; Labussière M; Ciccarino P; Marie Y; Delattre JY; Sanson M
    Neurology; 2012 Oct; 79(16):1693-8. PubMed ID: 23035067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
    Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
    Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IDH mutations occur frequently in Chinese glioma patients and predict longer survival but not response to concomitant chemoradiotherapy in anaplastic gliomas.
    Qi ST; Yu L; Lu YT; Ou YH; Li ZY; Wu LX; Yao F
    Oncol Rep; 2011 Dec; 26(6):1479-85. PubMed ID: 21874255
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C; Meyer J; Balss J; Capper D; Mueller W; Christians A; Felsberg J; Wolter M; Mawrin C; Wick W; Weller M; Herold-Mende C; Unterberg A; Jeuken JW; Wesseling P; Reifenberger G; von Deimling A
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical neuropathology practice news 2-2013: immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny.
    Preusser M; Bent Mv
    Clin Neuropathol; 2013; 32(2):82-3. PubMed ID: 23442355
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mutation analysis of IDH1 in paired gliomas revealed IDH1 mutation was not associated with malignant progression but predicted longer survival.
    Yao Y; Chan AK; Qin ZY; Chen LC; Zhang X; Pang JC; Li HM; Wang Y; Mao Y; Ng HK; Zhou LF
    PLoS One; 2013; 8(6):e67421. PubMed ID: 23840696
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of isocitrate dehydrogenase 1 mutation in 97 patients with glioma.
    Zhou YX; Wang JX; Feng M; Sun CM; Sun T; Chen GL; Du ZW
    J Mol Neurosci; 2012 Jul; 47(3):442-7. PubMed ID: 22113362
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas.
    Yokogami K; Yamasaki K; Matsumoto F; Yamashita S; Saito K; Tacheva A; Mizuguchi A; Watanabe T; Ohta H; Takeshima H
    Brain Tumor Pathol; 2018 Jul; 35(3):141-147. PubMed ID: 29931485
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
    Robinson C; Kleinschmidt-DeMasters BK
    J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.